Amgen's Kyprolis improves overall survival in blood cancer patients

(Reuters) – Amgen Inc said on Monday new data from a late-stage trial testing Kyprolis in combination with two other drugs showed improved overall survival rate in patients with blood cancer.


Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *